Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (s)-(n)-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl)propyl)-4-phenylpiperidin-4-yl)-n-methylacetamide
2. Sr 142801
3. Sr 142806
4. Sr-142801
5. Sr142801
1. 160492-56-8
2. Osanetant [inn]
3. Sr142801
4. Sr-142801
5. Sb-236984
6. Sr-14280
7. Sr-142806
8. Chembl346178
9. K7g81n94dt
10. N-(1-(3-((r)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidyl)propyl)-4-phenyl-4-piperidyl)-n-methylacetamide
11. N-(1-(3-((3r)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl)propyl)-4-phenyl-4-piperidinyl)-n-methylacetamide
12. Sr 142801
13. [3h]osanetant
14. (r)-n-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl)propyl)-4-phenylpiperidin-4-yl)-n-methylacetamide
15. Acetamide, N-[1-[3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl]-n-methyl-
16. N-(1-{3-[(r)-1-benzoyl-3-(3,4-dichloro-phenyl)-piperidin-3-yl]-propyl}-4-phenyl-piperidin-4-yl)-n-methyl-acetamide
17. Sr 142806
18. Unii-k7g81n94dt
19. N-[1-[3-[(3r)-1-(benzoyl)-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-n-methylacetamide
20. N-[1-[3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl]-n-methylacetamide
21. [3h]sr142801
22. [3h]sr142,801
23. Mls006010325
24. N-[1-[3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-n-methylacetamide
25. Schembl119440
26. Gtpl2110
27. Gtpl3480
28. Dtxsid901027521
29. Zinc3935475
30. Bdbm50291261
31. Pdsp1_001495
32. Pdsp2_001479
33. Akos015895948
34. Bcp9001032
35. Db04872
36. Ncgc00263110-01
37. Ncgc00263110-02
38. (s)-(n)-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl)propyl)-4-phenylpiperidin-4-yl)-n-methylacetamide
39. Acetamide, N-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl)propyl)-4-phenyl-4-piperidinyl)-n-methyl-, (r)-
40. Hy-14551
41. Smr004701389
42. Cs-0003438
43. Sr 142,806
44. Sr-142,801
45. E98685
46. Q7105703
47. Brd-k15646852-001-01-5
48. (s)-(+)-n-((3-[1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]prop-1-yl)-4-phenylpiperidin-4-yl)-n-methylacetamine
| Molecular Weight | 606.6 g/mol |
|---|---|
| Molecular Formula | C35H41Cl2N3O2 |
| XLogP3 | 7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 8 |
| Exact Mass | 605.2575829 g/mol |
| Monoisotopic Mass | 605.2575829 g/mol |
| Topological Polar Surface Area | 43.9 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 897 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Potential therapy for schizophrenia, depression and visceral pain.
Osanetant is a neurokinin-3 (NK3) receptor antagonist. Preliminary clinical trials have demonstrated that osanetant is superior to placebo on global assessment of efficacy and measures of positive symptoms in schizophrenia.
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
The mechanism of action of osanetant is uncertain at this point. Various preclinical data indicate that activation of NK3 receptors enhances the release of biogenic amines, including dopamine and serotonin. NK3 receptor antagonists could block NK3-receptor-mediated activation of these systems.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
34
PharmaCompass offers a list of Osanetant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Osanetant manufacturer or Osanetant supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Osanetant manufacturer or Osanetant supplier.
PharmaCompass also assists you with knowing the Osanetant API Price utilized in the formulation of products. Osanetant API Price is not always fixed or binding as the Osanetant Price is obtained through a variety of data sources. The Osanetant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Osanetant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Osanetant, including repackagers and relabelers. The FDA regulates Osanetant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Osanetant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Osanetant supplier is an individual or a company that provides Osanetant active pharmaceutical ingredient (API) or Osanetant finished formulations upon request. The Osanetant suppliers may include Osanetant API manufacturers, exporters, distributors and traders.
Osanetant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Osanetant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Osanetant GMP manufacturer or Osanetant GMP API supplier for your needs.
A Osanetant CoA (Certificate of Analysis) is a formal document that attests to Osanetant's compliance with Osanetant specifications and serves as a tool for batch-level quality control.
Osanetant CoA mostly includes findings from lab analyses of a specific batch. For each Osanetant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Osanetant may be tested according to a variety of international standards, such as European Pharmacopoeia (Osanetant EP), Osanetant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Osanetant USP).
